Hypertrophic Cardiomyopathy Pilot Study

Completed

• Conditions: Coronary Artery Disease; Hypertrophic Cardiomyopathy

• Registration Number: NCT02806479
• Lead Sponsor: Oregon Health and Science University

Brief Summary

This study evaluates mechanisms of arrhythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as well as to individuals free from arrhythmogenic substrate

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-06-16
• Study First Submitted QC: 2016-06-16
• Study First Posted: 2016-06-20
• Study Start: 2016-09
• Status Verified: 2020-09
• Primary Completion: 2020-09
• Study Completion: 2020-09
• Last Update Submitted: 2020-09-14
• Last Update Posted: 2020-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Diagnosed HCM
• Documented history of sustained ventricular tachyarrhythmia or resuscitated sudden cardiac arrest
• Maximal left ventricular wall thickness of > 30mm
• Extensive fibrosis on cardiac MRI (>15% of total myocardial volume)
• >7.5%/5-year risk of sudden cardiac death as determined by HCM risk-SCD

Read More

Exclusion Criteria

• age < 18 years
• Pregnancy
• Atrial Fibrillation

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Non-invasively reconstructed epicardial activation map	within one day

Trial Locations

Locations (1)

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States